Opinion Video March 7, 2025 Panelists discuss how they engage patients in shared decision-making by prioritizing open communication, discussing treatment options in the context of both clinical factors and patient preferences, and using strategies such as decision aids and detailed […]
Implementation of Shared Decision-Making in BTK Inhibitor Treatment Read More »
Opinion Video March 7, 2025 Panelists discuss proactive measures that health care teams can implement to manage adverse events associated with Bruton tyrosine kinase (BTK) inhibitors, such as early monitoring, dose adjustments, and supportive care, while emphasizing the importance of
Managing Adverse Effects and Adherence Read More »
Video content above is prompted by the following: How can different stakeholders such as providers, health systems, insurance providers, and pharmacy benefit managers work together more efficiently to optimize the uptake of biosimilars? Source link Ryan Haumschild, PharmD, MS, MBA,
The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars Read More »
Opinion Video February 28, 2025 Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma
Balancing Clinical Factors and Patient Preferences Read More »
Opinion Video February 28, 2025 Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), especially in the frontline setting, by offering effective, targeted therapy
Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL Read More »
Video content above is prompted by the following: How are providers positioning biosimilars in their treatment algorithms? What can be done to increase provider confidence in biosimilars? Source link Ryan Haumschild, PharmD, MS, MBA, CPEL
Positioning Biosimilars in Clinical Practice Read More »
Video content above is prompted by the following: How do you view patient confidence with biosimilars so far? What can be done to increase their confidence in biosimilars? Source link Ryan Haumschild, PharmD, MS, MBA, CPEL
Assessing Patient Confidence With Biosimilars Read More »
Opinion Video February 21, 2025 Panelists discuss how patient-reported outcomes and real-world evidence influence clinical decision-making when selecting Bruton tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). How do patient-reported outcomes
Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL Read More »
Opinion Video February 21, 2025 Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting emerging data that may refine their use in chronic lymphocytic leukemia (CLL)
Clinical Use of BTK Inhibitors in Management of CLL and MCL Read More »
Video content above is prompted by the following: What is the role of private label agreements and how can they enhance access to biosimilars? Source link Ryan Haumschild, PharmD, MS, MBA, CPEL
The Role of Private Label Agreements in Enhancing Access to Biosimilars Read More »
